“We recognize the importance of expanding our investor relations outreach,” said BioMark President and CEO Rashid Ahmed. “In recent years, the U.S. investment community has shown significant interest in the biotechnology sector and we are excited to introduce BioMark and our novel, disruptive technology to this receptive market. Given their understanding of the opportunity, and proven track record for establishing messaging that resonates with investors and increasing Street awareness for companies like BioMark, we view LHA as an ideal choice. LHA is the right partner for BioMark at the right time.”
Founded in 1984, LHA (formerly Lippert Heilshorn & Associates) is a leading provider of investor relations services. Staffed by a team of professionals with deep experience across multiple industry sectors, LHA partners with public and private companies to define objectives, set strategy and implement custom-designed programming utilizing industry best practices. By creating client identity and communicating strategic vision, LHA builds awareness, enthusiasm and sponsorship among target audiences to maximize shareholder value.
About BioMark Diagnostics Inc.
BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions that can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors. For more information, please visit www.biomarkdiagnostics.com.
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer